159 related articles for article (PubMed ID: 30324634)
1. Drug interactions with oral antineoplastic drugs: The role of the pharmacist.
Riu-Viladoms G; Carcelero San Martín E; Martín-Conde MT; Creus N
Eur J Cancer Care (Engl); 2019 Jan; 28(1):e12944. PubMed ID: 30324634
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interactions of cytostatics with regular medicines in lung cancer patients.
Rompelman FM; Smit AA; Franssen EJ; Crul M
J Oncol Pharm Pract; 2017 Oct; 23(7):483-490. PubMed ID: 27530243
[TBL] [Abstract][Full Text] [Related]
3. Description of pharmacist interventions during physician-pharmacist co-management of hypertension.
Von Muenster SJ; Carter BL; Weber CA; Ernst ME; Milchak JL; Steffensmeier JJ; Xu Y
Pharm World Sci; 2008 Jan; 30(1):128-35. PubMed ID: 17710561
[TBL] [Abstract][Full Text] [Related]
4. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience.
Lopez-Martin C; Garrido Siles M; Alcaide-Garcia J; Faus Felipe V
Int J Clin Pharm; 2014 Dec; 36(6):1251-9. PubMed ID: 25326824
[TBL] [Abstract][Full Text] [Related]
5. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
[TBL] [Abstract][Full Text] [Related]
6. Impact of pharmacist intervention in conjunction with outpatient physician follow-up visits after hospital discharge on readmission rate.
Arnold ME; Buys L; Fullas F
Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S36-42. PubMed ID: 25991594
[TBL] [Abstract][Full Text] [Related]
7. Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy.
Leenhardt F; Alexandre M; Guiu S; Pouderoux S; Beaujouin M; Lossaint G; Philibert L; Evrard A; Jacot W
Cancer Chemother Pharmacol; 2021 Oct; 88(4):723-729. PubMed ID: 34286354
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction.
Ribed A; Romero-Jiménez RM; Escudero-Vilaplana V; Iglesias-Peinado I; Herranz-Alonso A; Codina C; Sanjurjo-Sáez M
Int J Clin Pharm; 2016 Apr; 38(2):280-8. PubMed ID: 26715547
[TBL] [Abstract][Full Text] [Related]
9. [Interaction of oral form anticancer drugs with grapefruit juice].
Cholewka-Stafińska M; Polaniak R; Kardas M; Grajek M; Grochowska-Niedworok E
Pol Merkur Lekarski; 2017 Jan; 42(247):30-33. PubMed ID: 28134229
[TBL] [Abstract][Full Text] [Related]
10. Assessment of patient perceptions of counselling on oral antineoplastic agents by a dedicated cancer services pharmacist in an outpatient cancer clinic.
McNabb L; Metrot E; Ferrington M; Sunderland B; Parsons R; Copeland TS; Corscadden S; Tong S; Czarniak P
PLoS One; 2024; 19(6):e0304011. PubMed ID: 38870231
[TBL] [Abstract][Full Text] [Related]
11. Cross-sectional Census Survey of Patients With Cancer who Received a Pharmacist Consultation in a Pharmacist Led Anti-cancer Clinic.
Dennis M; Haines A; Johnson M; Soggee J; Tong S; Parsons R; Sunderland B; Czarniak P
J Cancer Educ; 2022 Oct; 37(5):1553-1561. PubMed ID: 35867307
[TBL] [Abstract][Full Text] [Related]
12. Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases.
Prely H; Herledan C; Caffin AG; Baudouin A; Larbre V; Maire M; Schwiertz V; Vantard N; Ranchon F; Rioufol C
J Cancer Res Clin Oncol; 2022 Mar; 148(3):707-718. PubMed ID: 33914124
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents.
Escudero-Vilaplana V; Ribed A; Romero-Jimenez RM; Herranz-Alonso A; Sanjurjo-Saez M
Eur J Cancer Care (Engl); 2017 May; 26(3):. PubMed ID: 26872286
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of pharmacist intervention in an emergency department.
Pérez-Moreno MA; Rodríguez-Camacho JM; Calderón-Hernanz B; Comas-Díaz B; Tarradas-Torras J
Emerg Med J; 2017 Aug; 34(8):495-501. PubMed ID: 27920036
[TBL] [Abstract][Full Text] [Related]
15. Impact of pharmacist interventions in older patients: a prospective study in a tertiary hospital in Germany.
Cortejoso L; Dietz RA; Hofmann G; Gosch M; Sattler A
Clin Interv Aging; 2016; 11():1343-1350. PubMed ID: 27713625
[TBL] [Abstract][Full Text] [Related]
16. Optimizing patient education of oncology medications: A descriptive survey of pharmacist-provided patient education in Canada.
Donald G; Scott S; Broadfield L; Harding C; Meade A
J Oncol Pharm Pract; 2019 Mar; 25(2):295-302. PubMed ID: 29020857
[TBL] [Abstract][Full Text] [Related]
17. Impact of a formal pharmacist-run oral antineoplastic monitoring program: A pilot study in an adult genitourinary oncology clinic.
Conliffe B; Figg L; Moffett P; Lauterwasser L; Parsons LB
J Oncol Pharm Pract; 2019 Jun; 25(4):777-786. PubMed ID: 29375014
[TBL] [Abstract][Full Text] [Related]
18. The impact of pharmacists' input to reduce serotonin syndrome drug interactions in an Australian hospital.
Khalil V; Chin K; Tran M; Furtula D
Int J Evid Based Healthc; 2016 Sep; 14(3):123-9. PubMed ID: 27552535
[TBL] [Abstract][Full Text] [Related]
19. Computerized physician order entry system combined with on-ward pharmacist: analysis of pharmacists' interventions.
Bedouch P; Tessier A; Baudrant M; Labarere J; Foroni L; Calop J; Bosson JL; Allenet B
J Eval Clin Pract; 2012 Aug; 18(4):911-8. PubMed ID: 21689216
[TBL] [Abstract][Full Text] [Related]
20. Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study.
Schlichtig K; Dürr P; Dörje F; Fromm MF
Clin Pharmacol Ther; 2021 Oct; 110(4):1075-1086. PubMed ID: 34118065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
